Pathophysiological Functions of CD30+ CD4+ T Cells in Rheumatoid Arthritis

Acta Medica Okayama

Volumn 57, Issue 6, 2003, Pages 267-277

  Okamoto, Akira ^a   Yamamura, Masahiro ^a   Iwahashi, Mitsuhiro ^a   Aita, Tetsushi ^a   Ueno, Akiko ^a   Kawashima, Masanori ^a   Yamana, Jiro ^a   Kagawa, Hidetoshi ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; CD30; CD4+ T cells; Interleukin 4 (IL 4); Rheumatoid arthritis (RA)

Indexed keywords

ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; STAINING; SYNOVIUM; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTIGENS, CD4; APOPTOSIS; ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-4; MALE; MIDDLE AGED; NF-KAPPA B; SIGNAL TRANSDUCTION; SOLUBILITY; SYNOVIAL MEMBRANE;

EID: 0942300586     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. + T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum (1998) 41: 1669-1676.
2. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L and Miossec P: Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 42: 963-970.
3. Miossec P: Are T cells in rheumatoid synovium aggressors or bystanders? Curr Opin Rheumatol (2000) 12: 181-185.
4. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B and Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 68: 421-427.
5. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M and Diehl V: Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 299: 65-67.
6. + T cells. J Immunol (1993) 151: 2380-2389.
7. Opat S and Gaston JS: CD30:CD30 ligand interactions in the immune response. Autoimmunity (2000) 33: 45-60.
8. + T cell clones in human immunodeficiency virus infection. J Exp Med (1994) 180: 2407-2411.
9. Bengtsson A, Johansson C, Linder MT, Hallden G, van der Ploeg I and Scheynius A: Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. J Leukoc Biol (1995) 58: 683-689.
10. + T cells producing Th2-type cytokines. FASEB J (1995) 9: 81-86.
11. Del Prete G, De Carli M, D'Elios MM, Daniel KC, Almerigogna F, Alderson M, Smith CA, Thomas E and Romagnani S: CD30-mediated signaling promotes the development of human T helper type 2-like T cells. J Exp Med (1995) 182: 1655-1661.
12. + T cells by IL-4 and IFN-γ. J Immunol (1997) 158: 2090-2098.
13. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H and Diamantstein T: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol (1989) 19: 157-162.
14. Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G, Almerigogna F, De Carli M and Pizzolo G: CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition. Eur J Immunol (1996) 26: 329-334.
15. + Th2-type gamma delta T cells in bronchial asthma. Mol Med (1995) 1: 821-826.
16. Piletta PA, Wirth S, Hommel L, Saurat JH and Hauser C: Circulating skin-homing T cells in atopic dermatitis. Selective up-regulation of HLA-DR, interleukin-2R, and CD30 and decrease after combined UV-A and UV-B phototherapy. Arch Dermatol (1996) 132: 1171-1176.
17. Leonard C, Tormey V, Faul J, Burke CM and Poulter LW: Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy (1997) 27: 780-786.
18. Dummer W, Rose C and Brocker EB: Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis. Arch Dermatol Res (1998) 290: 598-602.
19. Giacomelli R, Cipriani P, Lattanzio R, Di Franco M, Locanto M, Parzanese I, Passacantando A, Ciocci A and Tonietti G: Circulating levels of soluble CD30 are increased patients with systemic sclerosis (SSc) and corrlate with serological and clinical features of the disease. Clin Exp Immunol (1997) 108: 42-46.
20. Ihn H, Yazawa N, Kubo M, Yamane K, Sato S, Fujimoto M, Kikuchi K, Soma Y and Tamaki K: Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol (2000) 27: 698-702.
21. Seah GT and Rook GA: High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested reverse transcriptase-polymerase chain reaction; correlations with serum IgE levels. Scand J Infect Dis (2001) 33: 106-109.
22. Wang G, Hansen H, Tatsis E, Csernok E, Lemke H and Gross WL: High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med (1997) 102: 517-523.
23. + T cell involvement in the inflamed joints. Clin Exp Immunol (1995) 102: 547-550.
24. Gerli R, Bistoni O, Lunardi C, Giacomelli R, Tomassini C, Biagini P and Pitzalis C: Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy. Rheumatology (Oxford) (1999) 38: 1282-1284.
25. + T cells in rheumatoid synovitis: Mechanisms of recruitment and functional role. J Immunol (2000) 164: 4399-4407.
26. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J and Banchereau J: Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum (1990) 33: 1180-1187.
27. Simon AK, Seipelt E and Sieper J: Divergent T-Cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA (1994) 91: 8562-8566.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL and Hundder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 31: 315-324.
29. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D, Kaplan D, Koopman W, Longley S III, Mankin H, McShane DJ, Medsger T Jr, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, Rothschild B, Segal M, Sokoloff L and Wolfe F: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum (1986) 29: 1039-1049.
30. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H and Ota Z: The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum (1997) 40: 1096-1105.
31. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR and Modlin RL: Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science (1991) 254: 277-279.
32. Suzuki YJ, Mizuno M and Packer L: Signal transduction for nuclear factor-κB activation. Proposed location of antioxidant-inhibitable step. J Immunol (1994) 153: 5008-5015.
33. Schmid I, Krall WJ, Uittenbogaart CH, Braun J and Giorgi JV: Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry (1992) 13: 204-208.
34. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 184: 39-51.
35. + T cells in rheumatoid arthritis: A counter-regulatory paradigm for Th1-driven diseases. Trends Immunol (2001) 22: 72-77.
36. Gilfillan MC, Noel PJ, Podack ER, Reiner SL and Thompson CB: Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol (1998) 160: 2180-2187.
37. Liu MF, Kohsaka H, Sakurai H, Azuma M, Okumura K, Saito I and Miyasaka N: The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum (1996) 39: 110-114.
38. Thomas R and Quinn C: Functional differentiation of dendritic cells in rheumatoid arthritis: Role of CD86 in the synovium. J Immunol (1996) 156: 3074-3086.
39. Shimoyama Y, Nagafuchi H, Suzuki N, Ochi T and Sakane T: Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J Rheumatol (1999) 26: 2094-2101.
40. Firestein GS, Xu WD, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A and Zvaifler NJ: Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med (1988) 168: 1573-1586.
41. Chen E, Keystone EC and Fish EN: Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum (1993) 36: 901-910.
42. Elewaut D, De Keyser F, De Wever N, Baeten D, Van Damme N, Verbruggen G, Cuvelier C and Veys EM: A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis (1998) 57: 480-486.
43. Morita Y, Yamamura M, Kawashima M, Aita T, Harada S, Okamoto H, Inoue H and Makino H: Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int (2001) 20: 49-54.
44. Hargreaves PG and Al-Shamkhani A: Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol (2002) 32: 163-173.
45. Lee SY, Lee SY, Kandala G, Liou ML, Liou HC and Choi Y: CD30/ TNF receptor-associated factor interaction: NF-κB activation and binding specificity. Proc Natl Acad Sci USA (1996) 93: 9699-9703.
46. Phoneford WG, Nam SY, Podack ER and Miller RA:CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol (1997) 182: 125-136.
47. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL and Thompson CB: CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem (1996) 271: 12852-12858.
48. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hubinger G, Kieff E, Herrmann F, Leutz A and Gruss HJ: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor κB activation. Proc Natl Acad Sci USA (1996) 93: 14053-14058.
49. Duckett CS, Gedrich RW, Gilfillan MC and Thompson CB: Induction of nuclear factor κB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol (1997) 17: 1535-1542.
50. Duckett CS and Thompson CB: CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev (1997) 11: 2810-2821.